Production of growth factors, pro – and anti-inflammatory cytokines by postnatal MMSCs from various tissue sources during in vitro co-cultivation with immunoisolated pancreatic β-cells
- Authors: Goncharov A.G.1, Shupletsova V.V.1, Todosenko N.M.1, Goncharova E.A.1, Litvinova L.S.1
-
Affiliations:
- Immanuel Kant Baltic Federal University
- Issue: Vol 24, No 4 (2021)
- Pages: 477-482
- Section: SHORT COMMUNICATIONS
- Submitted: 16.07.2021
- Accepted: 20.08.2021
- Published: 15.10.2021
- URL: https://rusimmun.ru/jour/article/view/1058
- DOI: https://doi.org/10.46235/1028-7221-1058-POG
- ID: 1058
Cite item
Full Text
Abstract
The article presents the results of evaluating growth factors, pro – and anti-inflammatory cytokine production by multipotent mesenchymal stem cell cultures under the conditions of co-cultivation with immuno-isolated beta-cells of the pancreas. β-cell transplantation is a minimally invasive therapeutic approach (compared to transplantation of entire pancreas), and it provides better metabolic control with respect to insulin administration. However, when transplanting β-cells, there is always a risk of immune rejection of the grafted cells. It is generally recognized that encapsulation is an effective means of immunological protection against the recipient’s immune system during transplantation. Regulation of the autoimmune response to transplanted cells is crucial for the treatment of type I diabetes mellitus. In recent years, along with replacement of islet cells, much attention has been paid to the use of multipotent mesenchymal stem cells with immunomodulatory and/or immunosuppressive properties, aimed for the correction of diabetes mellitus. Either in vitro and in vivo, they impact not only T-lymphocytes, but also B-lymphocytes, dendritic and NK-cells. Mesenchymal stem cells are able to inhibit proliferation of immune cells and reduce their secretion of inflammatory cytokines, acting as auxiliary cells to improve the survival of islets in the early post-transplant phase. Combined transplantation of multipotent mesenchymal stem cells and pancreatic β-cells is a promising approach to the treatment of type I diabetes mellitus. Deeper study of the mechanisms that cause their cytoprotective effect upon the transplant may be helpful for implementation of this therapeutic approach and improve its efficiency. In our study, a 1% solution of low-viscosity sodium alginate with addition of saline solution (0.9% sodium chloride) was used to create immuno-insulating scaffolds, and a 2.2% BaCl2 solution was added for polymerization. Decreased production of proinflammatory cytokines (TNFα, IL-12, IL-5) and growth factor (GM-CSF) was registered in co-cultures of β-cells with mesenchymal stem cells of bone marrow origin, and those obtained from subcutaneous adipose tissue. Anti-inflammatory activity was more pronounced in adipose stem cells and their immunomodulatory effects were shown via changes of their cytokine-producing activity. Hence, the multipotent mesenchymal stem cells obtained from adipose tissue and bone marrow have shown to exert cytoprotective effect upon pancreatic beta-cells by shifting the cytokine-producing activity towards an antiinflammatory profile.
About the authors
A. G. Goncharov
Immanuel Kant Baltic Federal University
Author for correspondence.
Email: agoncharov59@mail.ru
ORCID iD: 0000-0001-6967-8838
PhD (Medicine), Senior Research Associate, Center for Immunology and Cell Biotechnologies
36010, Russian Federation, Kaliningrad, Pobedy ave., 189, apt 15
Phone: 7 (911) 865-20-66
Russian FederationV. V. Shupletsova
Immanuel Kant Baltic Federal University
Email: fake@neicon.ru
PhD (Biology), Senior Research Associate, Center for Immunology and Cell Biotechnologies
36010, Russian Federation, Kaliningrad, Pobedy ave., 189, apt 15
Russian FederationN. M. Todosenko
Immanuel Kant Baltic Federal University
Email: fake@neicon.ru
PhD (Biology), Research Associate, Center for Immunology and Cell Biotechnologies
36010, Russian Federation, Kaliningrad, Pobedy ave., 189, apt 15
Russian FederationE. A. Goncharova
Immanuel Kant Baltic Federal University
Email: fake@neicon.ru
Student, Medical Institute
36010, Russian Federation, Kaliningrad, Pobedy ave., 189, apt 15
Russian FederationL. S. Litvinova
Immanuel Kant Baltic Federal University
Email: fake@neicon.ru
PhD, MD (Medicine), Head, Center for Immunology and Cell Biotechnologies, Professor
36010, Russian Federation, Kaliningrad, Pobedy ave., 189, apt 15
Russian FederationReferences
- Le Blanc K., Tammik C., Rosendahl K. Zetterberg E., Ringdén O. HLA expression and immunologic propertiesof differentiated and undifferentiated mesenchymal stem cells / // Exp. Hematol. – 2003. – №31. – P. 890–896 doi: 10.1016/s0301-472x(03)00110-3
- Lee P.H., Kim J.W., Bang O.Y. Ahn Y. H., Joo I. S., Huh K. Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy /. // Clin Pharmacol Ther. – 2008. – №83. – P. 723–730. doi: 10.1038/sj.clpt.6100386
- Rasmussen J.G., Frobert О., Holst-Hansen С. Kastrup J., Baandrup U., Zachar V., Fink T., Simonsen U. Comparison of human adipose-derived stem cells and bone marrow-derived stem cells in a myocardial infarction model / // Cell Transplant. – 2014. – №23. – P. 195–206. doi: 10.3727/096368912X659871
- Remuzzi A., Cornolti R., Bianchi R. Figliuzzi M., Porretta-Serapiglia C., Oggioni N., Carozzi V., Crippa L., Avezza F., Fiordaliso F., Salio M., Lauria G., Lombardi R., Cavaletti G. Regression of diabetic complications by islet transplantation in the rat / // Diabetologia. – 2009. –№52. – P. 2653–2661. doi: 10.1007/s00125-009-1537-y
- Zappia E., Casazza S., Pedemonte E. Benvenuto F., Bonanni I., Gerdoni E., Giunti D., Ceravolo A., Cazzanti F., Frassoni F., Mancardi G., Uccelli A. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy / // Blood. – 2005. – №106. – P. 1755–1761. doi: 10.1182/blood-2005-04-1496.